Terry Murdock - G1 Therapeutics Senior Vice President - Development Operations
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
President
Mr. Terry L. Murdock is the Chief Operating Officer of G1 Therapeutics Inc. Mr. Murdock has served as our Chief Operating Officer since January 2019 and served as our Senior Vice President of Development Operations from August 2017 to December 2018. Prior to joining us, Mr. Murdock served as Vice President, Development Solutions of the Oncology Center for Excellence at IQVIA Holdings Inc., or IQVIA, from September 2014 to August 2015, and then as Vice President, Global Head of the Oncology Center for Excellence at IQVIA from August 2015 to July 2017. Prior to his tenure with IQVIA, Mr. Murdock served as President North America and a member of the board of directors of Ergomed Clinical Research, Inc., a wholly owned subsidiary of Ergomed plc, a publicly traded British pharmaceutical services company from 2012 to August 2014. Mr. Murdock also was Senior Vice President of ILEX Oncology Inc., or ILEX, and later Genzyme Corporationrationration, a biotechnology company, following its acquisition of ILEX from 2001 to May 2012 and Vice President of Research at The US Oncology Network, a healthcare services company from 1995 to 2001 since 2019.
| Age | 64 |
| Tenure | 5 years |
| Phone | 919 213 9835 |
| Web | https://www.g1therapeutics.com |
G1 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.192) % which means that it has lost $0.192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0901) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.G1 Therapeutics currently holds 57.17 M in liabilities with Debt to Equity (D/E) ratio of 1.24, which is about average as compared to similar companies. G1 Therapeutics has a current ratio of 4.66, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about G1 Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ezio Bonvini | MacroGenics | 70 | |
| Joseph Newell | Atara Biotherapeutics | 54 | |
| Jeffrey Peters | MacroGenics | 53 | |
| Juan Jaen | Arcus Biosciences | 66 | |
| Jason Fontenot | Sangamo Therapeutics | 54 | |
| Thomas Ottoboni | Heron Therapeuti | 65 | |
| David Szekeres | Heron Therapeuti | 50 | |
| Michael Mathews | Heron Therapeuti | 61 | |
| Sarah Cooley | Fate Therapeutics | N/A | |
| James Doherty | Acumen Pharmaceuticals | 56 | |
| Christopher Murray | Blueprint Medicines Corp | 61 | |
| Thomas Spitznagel | MacroGenics | 57 | |
| Sean Ristine | Heron Therapeuti | 54 | |
| Fouad MD | Blueprint Medicines Corp | 55 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| Bahram MBA | Fate Therapeutics | 47 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 |
G1 Therapeutics Leadership Team
Elected by the shareholders, the G1 Therapeutics' board of directors comprises two types of representatives: G1 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GTHX. The board's role is to monitor G1 Therapeutics' management team and ensure that shareholders' interests are well served. G1 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, G1 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Monica Thomas, General Officer | ||
| Jay Strum, Chief Scientific Officer | ||
| Andrew Perry, Chief Officer | ||
| Jeff Macdonald, Head of Investor Relations/Public Relations | ||
| Jennifer CPA, Chief Officer | ||
| Alexander MS, VP Operations | ||
| John V, Chief Officer | ||
| ChB MB, Chief RD | ||
| Terry MSc, Chief Officer | ||
| John Bailey, President CEO | ||
| William Roberts, Vice Communications | ||
| Mark Avagliano, Chief Officer | ||
| Evan MBA, Vice Marketing | ||
| Terry Murdock, Senior Vice President - Development Operations |
GTHX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is G1 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |